Leading the way in stroke recovery

Dr. Leo Petrossian is the Chief Executive Officer of Kandu Inc., a neurotechnology company formed from the merger of Neurolutions and Kandu Health. He is a seasoned healthcare executive and entrepreneur with deep expertise in bringing transformative medical devices from early development to commercialization. Under his leadership, Neurolutions pioneered the IpsiHand®, the first FDA-cleared brain–computer interface for stroke rehabilitation. Dr. Petrossian is passionate about advancing technologies that expand access, improve outcomes, and reshape standards of care in neurology and beyond.

Dr. Petrossian earned his MBA from the UCLA Anderson School of Management in 2014 and earned his Ph.D. & MS in Biomolecular Nanotechnology & Solid-State Device Physics as an NSF IGERT fellow at Arizona State University in 2007. He also holds a double B.S. in Electrical Engineering & Biomedical Engineering from California State University, Long Beach.

Nabeel is the Chief Financial Officer of Kandu, Inc. Prior to joining Kandu, he was the Chief Financial Officer of Outset Medical, Inc., a medical dialysis technology company. Prior to Outset Medical, Nabeel held a variety of finance leadership roles, including as Vice President, Finance at 8×8, Inc., a communications platform provider, and at Vocera Communications, Inc., a provider of clinical workflow solutions. Previously, he held various leadership positions in accounting and finance, including as CFO of Wanderful Media as well as CFO of MarketTools, Inc. Earlier in his career, he served in positions of increasing responsibility at Ernst & Young, LLP and at eBay, Inc. Nabeel holds a Bachelor of Commerce degree from Laurentian University, and an M.B.A., from the Wharton School, University of Pennsylvania.

Kirsten has over 20 years of experience in stroke with various leadership roles at Boston Scientific, Stryker, and Imperative Care. She was the Founder and Chief Executive Officer of Kandu Health and became the Chief Marketing Officer and General Manager of Clinical Services at the conclusion of the merger with Neurolutions in March 2025. Kirsten holds several patents in the fields of stroke treatment and detection, and she is the author of several peer-reviewed papers in the field of stroke and access to care.

Andy Schultz is the Chief Commercial Officer of Kandu, Inc.  Previously, Andy was the  SVP of Revenue and Operations at Candid, a disruptor in the orthodontic clear aligner space.

Prior to Candid, Andy was the Vice President Customer Experience and Planning at Scotts Miracle-Gro. Over 13 years there he held various leadership roles in sales, operations, strategy and supply chain. Prior to that time, Andy was a First Officer for Northwest Airlink. He served 8 years in the US Navy aboard the USS Enterprise and as a part of the Blue Angels Flight Demonstration Squadron. Andy graduated from Embry-Riddle Aeronautical University.

With over 35-years of experience in healthcare leadership, Javad has extensive experience in overall operations (product development,manufacturing and QA/RA) on a global scale, including North America, Europe, Latin America, and Asia.

Javad has held executive roles at Gambro , Toshiba Medical Systems, Bayer Healthcare, Siemens Healthcare, and NovaSignal and Nile.ai.

Javad’s business-oriented approach extends to product development and operational excellence. He has been instrumental in streamlining processes, reducing product costs, and implementing efficient organizational designs. His leadership has been crucial in driving product development strategies that align with regulatory compliance and market needs.

Seth Wilk is the Chief Innovation Officer at Kandu, Inc., with 20 years of experience in research, development, and intellectual property. He has authored over 100 publications and patents, secured more than $50M in federal grant funding, and led multiple clinical studies and trials. Dr. Wilk earned his PhD and MS in Biomolecular Nanotechnology as an NSF IGERT Fellow at Arizona State University in 2005, and holds a BS in Electrical Engineering from The College of New Jersey.

Nancey Trevanian Tsai, MD is a Diplomate of the American Board of Physical Medicine and Rehabilitation. She is the Associate Program Director of the HCA Trident Healthcare PM&R Residency, Eta Kappa Nu, Senior Member, and Chair of the South Carolina section of the IEEE. She has served as a past Chair of the American Council on Exercise and past Chair of the South Carolina Medical Association Young Physicians Section. She has a patent for the Blink Reflexometer in Australia and Japan, and the United States. She is a mother, a musician, and a former Olympic athlete and coach.

Eric C. Leuthardt, M.D. is a highly regarded neurosurgeon and professor at Washington University in St. Louis. He holds positions in several departments, including Neurological Surgery, Neuroscience, Biomedical Engineering, Mechanical Engineering, and Material Sciences, and serves as the Chief of the Division of Neurotechnology. Leuthardt is known for his innovative research in the field of neuroprosthetics, neurotechnologies, advanced brain imaging, and neurosurgical devices.

His work has earned him recognition as a pioneer in applied neuroscience and he has over 1800 patents filed with the US Patent and Trademark Office for various medical devices and brain-computer interface technologies. In addition to his academic and research achievements. He is also a successful entrepreneur, having founded eight startup companies. He is an Emmy Award-winning playwright and the author of two fiction novels.

Internationally acclaimed neurologist and researcher, Tudor G. Jovin, MD, is based at Cooper University Hospital in Camden, New Jersey, and presides as the Chief and Chairman of Cooper Neurological Institute. Dr. Jovin is an expert in the interventional and non-interventional treatment for the entire spectrum of stroke and cerebrovascular disorders. He was one of the nation’s first interventional neurologists, a medical subspecialty that uses minimally invasive technologies applied from within the vessels to diagnose and treat diseases of the arteries and veins of the head, neck, and spine such as acute stroke, carotid stenosis, intracranial aneurysm, and arteriovenous malformations. In addition to his clinical experience, Dr. Jovin is known internationally for his research activities. He has served as principal investigator for several international clinical studies, including REVASCAT, a randomized trial of endovascular therapy versus medical therapy for acute stroke within eight hours of symptoms onset conducted in Spain, and DAWN, a multicenter, international, randomized trial of endovascular therapy versus medical therapy in the beyond eight-hour time window. Both studies are considered landmark studies in the development of treatments for acute stroke and have been published in the New England Journal of Medicine. He is a member of the executive or steering committees for several multicenter national and international trials, and has participated as site principal investigator or co-investigator in multiple national and international trials. Additionally, he serves as editorial board member for numerous medical journals. Dr. Jovin has published more than 300 articles in peer-reviewed journals or book chapters. The consequential nature of his research is evidenced by recently published studies that have identified Dr. Jovin as the highest impact author in the neuro-interventional field. Prior to joining Cooper, Dr. Jovin was a professor of neurology and neurosurgery at the University of Pittsburgh School of Medicine and director of the Center for Neuroendovascular Therapy at the University of Pittsburgh Medical Center (UPMC). At UPMC, he also served as the director of UPMC’s Stroke Institute, one of the leading centers for stroke care, education, and research in the world.